Programme (nur in Englisch)

Funded projects
Men's Health Partners
We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact.
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“The number of men taking their own lives around the world is one of the biggest challenges of our time. Movember is working to ensure all men and boys look after their mental health and are comfortable to seek help when they’re struggling.”
Brendan Maher, Global Director, Mental Health and Suicide Prevention.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

Prognostic relevance of expression levels of selected microRNA

Movember Funding to Date

EUR 49,500

What we seek to achieve

To better understand host-gene-expressions associated with aggressive tumor characteristics and poor life expectancy in prostate cancer

Implemented by
Foerderverein Hilfe bei Prostatakrebns e.V.
Project start date
February 2015
Project Status
In Progress

About the project

This project aims to look at whether the expression of specific genes in prostate cancer  are associated with aggressive tumor characteristics and poor life expectancy. This will be done by targeting specific gene expression using miRNA technology. 

In situ hybridization, immunohistochemistry and tissue microarrays will be used to determine prognostic outcomes for prostate cancer patients. 

The Expertise on this project include: 
Prof. Dr. Dr. h.c. Manfred Wirth 
Dr. Kati Erdmann
Prof. Dr. G. Baretton
Prof. Dr. L. Hofbauer

Page 1 of 29